Clinical Trial Update: A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer. [Phase 2]

View source ↗

Summary

The document reports the completion of a Phase II trial evaluating LY231514 (MTA) in combination with gemcitabine for metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• LY231514 (MTA) (LY231514)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED